<DOC>
	<DOC>NCT00126165</DOC>
	<brief_summary>This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.</brief_summary>
	<brief_title>Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer</brief_title>
	<detailed_description>This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Stage T1 and T2 prostate cancer Prostate specific antigen (PSA)&gt;=20 and Gleason score&lt;=6 PSA&lt;=15 and Gleason score 7 Signed informed consent No hip prosthesis, pins or screws No previous pelvic radiotherapy No inflammatory bowel disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>hypofraction</keyword>
	<keyword>radiosensitivity</keyword>
	<keyword>image-guidance</keyword>
</DOC>